Descrizione Clinica
Antifungal Azolmen soluz 30ml 1% Azolmen
AZOLMEN
active ingredients
Cream 100 g cream contain: Active ingredient: bifonazole 1 g. Excipient with known effects: cetilstearilic alcohol. Ice cream 100 g gel contains: Active Ingredient: bifonazole 1 g. Skin solution 100 mL solution contain: Active Ingredient: bifonazole 1 g. Skin powder 100 g of powder contain: Active Ingredient: bifonazole 1 g. For the full list of excipients see paragraph 6.1.Excellent
Cream monostearate sorbitan; polysorbed 60; sperm; cetilstearilic alcohol; octyldodecanol; benzilic alcohol; purified water. Ice cream hetoxyl fat alcohol mixture; hetoxyl fatty acids glycerides; isopropylsostearate; ethyl alcohol; lactic acid; benzyl alcohol; purified water. Skin solution ethanol; isopropylmirate. Skin powder rice starch not gelable.Therapeutic indications
Cream, gel and skin solution Dermatomycosis supported by dermatophytes (e.g. tricophytes), saccaromycetes (e.g. Candida) and other pathogenic fungi (e.g. furfur disease). Dermatosis from overinfections supported by the aforementioned pathogenic mushrooms and sensitive germs in Azolmen. Within these affections are included plantar and interdigital mycosis of the hand and foot (athlete foot); onicomycosis, mycosis of the trunk and skin folds, pityriasis versicolor. Skin powder Azolmen powder is indicated for the therapy of wet skin mycosis and skin folds especially if located in areas usually covered or poorly aerated (e.g. wrapping dermatitis, interdigital mycosis) as well as as as a coadjuvant of treatment with Azolmen cream, gel and skin solution.Contraindications
Hypersensitivity to the active ingredient or any of the excipients listed in paragraph 6.1.Population
Cream, gel and skin solution Save different prescription Azolmen should be applied in small quantities on infected parts with a slight massage once a day, preferably in the evening before bedtime. Azolmen cream and gel are selectively indicated for the treatment of the skin areas discovered. Azolmen gel, thanks to the refreshing power of its components is particularly useful in cases where an inflammatory component is associated with burning sensation and/or skin itching. Given the high activity of Azolmen it is usually sufficient to apply a small amount (e.g. 1⁄2 cm of cream or gel) to cover a surface of the size of a palm hand. Azolmen skin solution is especially useful for treating skin areas covered with hair and fungal infections at skin folds, with the exception of mucous membranes. Azolmen cream, gel and cutaneous solution is odorless, not stain and can be easily removed with water. For the purposes of complete healing, the controlled and sufficiently prolonged use of Azolmen is indispensable. It is recommended not to stop therapy immediately after the disappearance of acute flogistic manifestations and subjective symptomatology, but to stick to the following average treatment times, depending on the type of infection, extension and location of the infection itself:| tinea pedis | 3 weeks |
| tinea corporis, tinea manuum, tinea cruris | 2–(3) weeks |
| pityriasis versicolor | 2 weeks |
| superficial skin candidiasis | 2–(4) weeks |
Conservation
This medicine does not require any special condition of conservation.Warnings
The use, especially if prolonged, of medicinal products for skin use, can give rise to phenomena of sensitization; in such case, it is necessary to stop treatment and establish suitable therapy. We will also be involved in the development of resistant microorganisms. Pediatric population In the very early childhood, the medicine should only be used in case of actual need and under the direct control of the doctor. Important information about some excipients: AZOLMEN cream contains cetilstearilic alcohol that can cause local skin reactions (e.g. contact dermatitis)Interactions
Bifonazole interactions with other medicines or other forms of interaction are not reported in literature.Effects
Azolmen cream, gel, solution and powder is perfectly tolerated. Only in rare cases can a slight and mostly transient redness of the skin arise and more rarely a sense of burning and irritation that normally disappear quickly. Reporting of suspicious adverse reactions The reporting of suspicious adverse reactions occurring after the authorization of the medicinal product is important, as it allows continuous monitoring of the benefit/risk ratio of the medicinal product. Healthcare workers are required to report any suspected adverse reaction via the national reporting system at the address www.agenziafarmaco.gov.it/it/responsabili.Overdosing
There are no reports of toxic effects of bifonazole referring to overdose.In pregnant women the medicinal product should only be used in case of actual need and under the direct control of the doctor.
Source: Farmadati